Clinical Trials Browser

Phase 3 × Peritoneal Neoplasms × Carboplatin × Clear all

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Phase 3 Completed

1,367 enrolled 29 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04498117 2026-04-01

FLORA-5

Phase 3 Active not recruiting

615 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03038100 2023-02-17

IMagyn050

Phase 3 Completed

1,301 enrolled 22 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01462890 2022-07-20

BOOST

Phase 3 Completed

927 enrolled

Gynecologic

Fallopian Tube Neoplasms, Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01015118 2017-12-07

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Phase 3 Completed

1,366 enrolled 17 charts

Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

NCT00382811 2016-07-18

OVATURE

Phase 3 Completed

142 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00191646 2011-03-04

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Phase 3 Completed

919 enrolled 18 charts

Gynecologic

Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms

Clinical Trials

FRAmework-01

KEYLYNK-001

FLORA-5

IMagyn050

BOOST

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

OVATURE

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy